2011
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. British Journal Of Cancer 2011, 105: 1830-1838. PMID: 22033270, PMCID: PMC3251880, DOI: 10.1038/bjc.2011.456.Peer-Reviewed Original ResearchConceptsCell death markersAdvanced tumorsPharmacodynamic biomarkersApoptotic markersPhase 1a studyPhase 1a trialDeath receptors DR4Colo205 tumorsSerum 8Patients 24Active caspase-3Patient seraColo205 xenograftsEvidence of activitySubsequent cell deathCytokeratin 18PatientsTransient increaseDulanerminReceptors DR4TumorsCaspase-3SerumCaspase-3/7Significant increase
2007
Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors
Pan Y, Xu R, Peach M, Huang C, Branstetter D, Durbin B, Herbst R, Eckhardt G, Mendelson D, Holland P. Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. Journal Of Clinical Oncology 2007, 25: 3535-3535. DOI: 10.1200/jco.2007.25.18_suppl.3535.Peer-Reviewed Original ResearchGenomic DNAApo2L/TRAILRhApo2L/TRAILCaspase-3/7Advanced tumorsApoptotic markersPharmacodynamic assayEffector caspase 3/7TRAIL activityCaspase 3/7 levelsDeath inducingRecombinant human Apo2L/TRAILLigand bindingActive caspase-3Phase Ia studyReal-time PCRCellular apoptosisReceptors DR4Caspase-3Patient serum samplesTaqMan real-time PCRColo205 tumorsSerum 8M30 ELISASarcoma patients